● OUR STORY ●
Entrepreneurism is in our DNA. ABC² was founded by a legendary family of innovators in finance, technology, and philanthropy. In 2001, Dan Case was diagnosed with brain cancer. Dan, together with his wife, Stacey, his brother, Steve, and Steve’s wife, Jean, founded ABC² after seeing how little progress and focus there had been on brain tumors.

● OUR MISSION ●
We invest in research aimed at finding the fastest possible routes to a cure for brain cancer.

● OUR UNCONVENTIONAL APPROACH ●
Brain cancer breakthroughs don’t follow conventional wisdom. Neither do we. ABC² believes that the status quo for brain tumor patients is not acceptable. We are scientists, entrepreneurs, and aggressive problem solvers who believe that we can change the prognosis for patients with brain tumors.

● WAYS TO GIVE ●
Help our cutting-edge scientific ventures by donating. Your dollars will advance breakthrough research projects desperately in need of funding.

Donate online: abc2.org/donate
Donate by mail:
ABC²
1717 Rhode Island Avenue, N.W.
Suite 700
Washington, D.C. 20036

For more information, visit abc2.org

● ANNUAL FUNDRAISING EVENTS ●
abc2.org/events
Florida Brain Cancer 5K, Lake Worth, FL
Race for Hope 5K, Washington, D.C.
Over The Edge for Brain Cancer, Washington, D.C., San Diego, CA and San Francisco, CA

● FUNDRAISING EVENT SPONSORSHIP ●
National and local businesses are integral to the success of our community fundraising events. By becoming an event sponsor, company team or in-kind donor, companies will gain brand exposure while helping boost fundraising dollars.

ABC²
1717 Rhode Island Avenue, N.W.
Suite 700
Washington, D.C. 20036

Contact us at info@abc2.org or 202-419-3140.

“Breakthroughs in brain cancer research don’t follow conventional wisdom. Neither do we.”

abc2.org
IMPACT
Our work centers on a single goal—advancing effective new treatments for brain cancer. We evaluate all of our grants, investments and partnerships on their potential to positively impact the way that brain tumor patients are treated. Since our founding in 2001, we have helped bring 28 different treatments into the clinic.

LEADERSHIP
ABC2 (Accelerate Brain Cancer Cure) speeds the development of effective new brain tumor treatments by identifying and funding the most promising research at leading research centers and biopharmaceutical companies. We focus on high-risk, high-reward projects that might not move forward without our pivotal backing. We “buy down” risk so that our partners can better drive the creation of innovative new treatments.

LEVERAGE
We partner with biotech and pharmaceutical companies, investors and other foundations to bring more resources to the most promising research. We believe in the power of networks, working with the best, brightest and most passionate scientific partners and collaborators. We break through boundaries of academia, nonprofits, and industry to help our partners connect, learn from our failures and share in each other’s successes.

CURRENT RESEARCH PROJECTS

**Precision Medicine**
ABC2’s genetic tumor profiling project, Allele, is a collaboration with The Broad Institute of MIT and Harvard and leading cancer centers to bring together the best in cancer research and the best in cancer treatment. We believe this first-of-its-kind model could transform brain tumor research approaches and clinical practice.

Allele produces, at no cost to patients, whole-exome, rapid turnaround, CLIA-certified, pathologist-reviewed, computerized reporting of pertinent genomic information for both normal and tumor tissue. Patients and their physicians are using this information to access the most effective treatments for their exact tumors. Allele also provides guidance for patient treatment in INSIGHT—the world’s first adaptive clinical trial for brain tumor patients currently being launched at the Dana-Farber Cancer Institute.

**Drug Repurposement**
We’re speeding new treatments for brain cancer patients with drugs developed for other diseases. Our work with Genentech on Avastin is a good example. Originally, Avastin was a drug developed for colon cancer, but we funded the early clinical trial work to validate the effectiveness of Avastin to treat brain tumors. Currently, we’re investing in a project to potentially repurpose a drug originally used to treat parasitic infection.

**Improved Diagnostics**
We created a consortium of more than a dozen leading medical centers to develop and test a system that can detect brain tumor genetic mutations in a patient’s blood or spinal fluid. Our goal is to provide patients with reliable diagnostic information so that they no longer have to undergo invasive biopsies or rely on fuzzy MRI images.

**Immunotherapy**
Immunotherapy harnesses and enhances the powers of the body’s own immune system to fight cancer. Because of the immune system’s unique properties, these therapies may hold greater potential than current treatment approaches to improve patients’ lives with fewer side effects.

We’ve long been interested in immunotherapy, providing early funding for the Duke poliovirus therapy as well as for a number of the most promising brain tumor vaccines in clinical trials today, including:

- Duke research developed by Celldex
- UC San Francisco research developed by Agenus
- UCLA research developed by Northwest Biotherapeutics

More recently, we have helped the University of Florida establish a state-of-the-art immunotherapy program. We’ve also invested in a cutting-edge split immunity clinical trial for GBM patients at the Sourasky Medical Center of Tel Aviv University and a personalized neoantigen vaccine (NeoVax) for brain cancer being developed at Dana-Farber.

OVER $20 MILLION INVESTED IN BRAIN TUMOR RESEARCH • abc2.org